New data for AbbVie's eight-week pan-genotypic HCV regimen

AbbVie Inc. (NYSE:ABBV) said an eight-week regimen of ABT-493 plus ABT-530 led to SVR12 rates of 97-98% in HCV genotype 1, 2 and 3 patients in the ongoing Phase II SURVEYOR-I and SURVEYOR-II trials. AbbVie shares rights to ABT-493 with Enanta Pharmaceuticals Inc. (NASDAQ:ENTA).

In both treatment-naive and treatment-experienced non-cirrhotic HCV subjects, the regimen led to an SVR12 in 33 of 34 HCV genotype 1 patients and 53 of 54 genotype 2 patients. The eight-week regimen led to an SVR12 in 28 of 29 treatment-naive non-cirrhotic HCV genotype 3 patients. ...